openPR Logo
Press release

Monoclonal Antibody Diagnostic Reagents Market Dynamics 2019 By Key Pkayers: AnaSpec, BioGenex, Bio-Rad, Biocare Medical, BioVision, Celltrion, Creative Diagnostics, GenWay Biotech, Innovent Biologics

05-15-2019 05:43 AM CET | Health & Medicine

Press release from: Coherent Market Insights - Biotechnology Industry

Monoclonal Antibody Diagnostic Reagents

Monoclonal Antibody Diagnostic Reagents

Increasing use of monoclonal antibodies in various R&D applications, cancer therapies, and immunological disorders is expected to drive growth of the global monoclonal antibody diagnostic reagents market size. Monoclonal antibody diagnostic kits are increasingly used to detect communicable diseases including transfusion transmissible infections (TTI). According to World Health Organization (WHO) data of 2017, each year about 15 million people die due to infectious diseases in emerging economies. Tropical parasitic infections such as schitosomiasi and sexually transmitted infections such as syphilis also cause morbidity. There is an urgent need for development of accurate, simple, and stable diagnostic tools.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2048

Non-infectious diseases are the leading cause of mortality and morbidity worldwide. As per the WHO 2017 data, around 40 million individuals suffering from cardiovascular diseases, cancer, chronic respiratory diseases, diabetes, and stroke die every year across the globe. Prevailing cancer incidence rate are expected to fuel demand for disease diagnosis. According to International Agency for Research on Cancer (IARC), the incidence of cancer is expected to reach to 26.8 million new cases and 17.1 million deaths annually by the year 2030.

Monoclonal antibodies are effective biological reagents in immunodiagnostic assays due to their binding accuracy to many pathogens, thereby, making it an important research tool. Despite many advantages and applications offered by monoclonal antibodies, it is difficult to get the right antibodies and attach a compound to it. Monoclonal antibodies need considerable amount of time, money, and manpower to produce them which can hinder the market size to some extent.

Diagnostic tests based on the use of MAbs as reagents are routinely used in enzyme-linked immunosorbent assays and radioimmunoassay in laboratories. These tests measure the circulating concentrations of hormones (gastrin, growth hormone, human chorionic gonadotropin, insulin, progesterone, thyroid stimulating hormone, thyroxine, triiodothyronine, and renin) and cell products (blood clotting factors, blood group antigens, histocompatibility antigens, interferon, interleukins, and tumor markers).

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2048

Monoclonal antibodies play a valuable role in diagnostic medicine during tests to determine the concentration of specific proteins in blood or urine. For instance, high blood level of a prostate-specific antigen, measured by its interaction with a monoclonal antibody, provides an early warning for prostate cancer. Antibodies to target biomarkers are widely used for detecting carcinogenic-embryonic antigen (colorectal cancer), prostate specific antigen (expressed in prostate cancer), CA125 (ovarian cancer), CA19-9 (gastrointestinal cancer), CA15-3 antigen, and HER-2/neu proteins (breast cancer).

Asia Pacific monoclonal antibody diagnostic reagents market is expected to exhibit the highest growth rate, due to rising incidence of lifestyle-induced diseases coupled with rising population base demanding disease diagnosis. According to WHO data, non-communicable diseases deaths are projected to increase by 15% between 2010 and 2020, with the highest numbers predicted in the Western Pacific (12.3 million deaths) and South-East Asia (10.4 million deaths) regions.

Request A consult-us @ https://www.coherentmarketinsights.com/insight/consult-us/2048

Key players operating in the monoclonal antibody diagnostic reagents market include AnaSpec, BioGenex, Bio-Rad, Biocare Medical, BioVision, Celltrion, Creative Diagnostics, GenWay Biotech, Innovent Biologics, Medix Biochemica, Qiagen, and Teva Pharmaceutical Ltd.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Monoclonal Antibody Diagnostic Reagents Market Dynamics 2019 By Key Pkayers: AnaSpec, BioGenex, Bio-Rad, Biocare Medical, BioVision, Celltrion, Creative Diagnostics, GenWay Biotech, Innovent Biologics here

News-ID: 1739295 • Views: 437

More Releases from Coherent Market Insights - Biotechnology Industry

CRISPR and CAS Gene Market – Insights By Top Key Players: Caribou Biosciences …
Manufacturers in the CRISPR and CAS gene are collaborating with many companies for sponsoring clinical trials. Editas Medicine has licensed CRISPR and other gene editing patent rights from the Broad Institute, the Massachusetts Institute of Technology (MIT), Harvard University, and others. In March 2017, Editas reportedly entered into an agreement with Irish pharmaceutical company Allergan under, which Editas was to receive a US$ 90 million up-front payment for an option
Monoclonal Antibody Therapeutics - launch of novel monoclonal antibodies: Pfizer …
Introduction and supposed success of monoclonal antibodies and other biological products has spurred the interest of manufacturers in these therapies. Success of popular monoclonal antibodies such as Avastin, Herceptin, and Rituxan (revenues as US$ 6.8 Bn, US$ 7.1 Bn, and US$ 5.9 Bn respectively in 2017 globally) has spurred manufacturers’ interest in these therapies. Leading manufacturers have resorted to boosting pipeline through various ways such as merger and acquisitions, partnerships,
Recombinant Human Endostatin Market Witness Significant Growth | Pfizer Inc., No …
Increasing research and development activities for identifying potential uses of recombinant human endostatin is expected to propel growth of the market. For instance, according to a paper published in the journal Nature, September 2015, a study was conducted to evaluate effects of recombinant human endostatin in combination with radiotherapy for treating esophageal squamous cell carcinoma and to discover its potential mechanisms. These findings suggested that recombinant human endostatin is a
Immune Anti-Inhibitor Market Industry Insights 2027 By Key Players: Shire Plc, B …
Researchers are working on analyzing the risks associated with use of replacement factors, as in which replacement factors are more prone to facilitate development of antibodies. For instance, World Federation of Haemophilia (WFH) announced results from study published in journal ‘Blood’ in 2014, which demonstrated higher incidence of Inhibitor development after treatment with Kogenate FS/Bayer/Helixate NexGen replacement factor. The World Federation of Haemophilia has requested the U.S. Food & Drug

All 5 Releases


More Releases for Monoclonal

Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024
" Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024" Report Highlights: * Significance for Monoclonal Antibodies for Cancer Treatment * Global Cancer Monoclonal Antibodies Market Overview * Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication * Global Cancer Monoclonal Antibodies Pipeline: 697 mAb * Marketed Cancer Monoclonal Antibodies: 60 * Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion The recent years have witnessed the emergence of monoclonal antibodies, which has the potential
Monoclonal Antibodies market In Depth overview by Experts 2018
The Monoclonal Antibodies market outlook of the global industry is provided based on the Monoclonal Antibodies growth drivers, constraints and threats, SWOT analysis, and Monoclonal Antibodies market share study. The drivers and constraints of Monoclonal Antibodies industry recognize the rise and fall of the Monoclonal Antibodies market. The study is served based on the Monoclonal Antibodies haggling power of buyers, haggling power of suppliers, the risk of new entrants, the
Monoclonal Antibody Custom Service Market Ravishing Growth with CAGR of 10.84% | …
Complete Study of Monoclonal Antibody Custom Service Market Research Report is added on MarketResearchFuture.com with Latest Advancement. Detail analysis on possible segments and sub segments of the market. Along with this regional analysis of the market which includes North America, Europe, Asia Pacific and Middle East and Africa. Avail Premium Sample Copy @ https://www.marketresearchfuture.com/sample_request/4515 Monoclonal Antibody Custom Service Market – Overview It is estimated that monoclonal antibody custom service market is expected to
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Cancer Monoclonal Antibodies Pipeline Analysis
In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies. In recent years the popularity
Global Monoclonal Antibodies Pipeline Insight 2015
Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality.